Are there antibody-drug conjugates approved for Carcinoid Tumors

Antibody-Drug Conjugates for Carcinoid Tumors

Based on current medical guidelines, there are no FDA-approved antibody-drug conjugates (ADCs) specifically for carcinoid tumors at this time.

What This Means

Carcinoid tumors are neuroendocrine tumors (NETs) that arise from hormone-producing cells. According to the NCCN Guidelines for Neuroendocrine and Adrenal Tumors (Version 3.2025), the standard treatment approaches for advanced carcinoid tumors typically include:

• Somatostatin analogs (octreotide LAR, lanreotide) - to control hormone-related symptoms
• Peptide receptor radionuclide therapy (PRRT) with lutetium Lu 177 dotatate - a targeted radioactive treatment
• Chemotherapy (cisplatin/etoposide, carboplatin/etoposide, temozolomide)
• Targeted therapies like everolimus or cabozantinib
• Immunotherapy (pembrolizumab) for specific biomarker-positive tumors

Why ADCs Might Be Relevant

While ADCs aren't currently approved for carcinoid tumors specifically, they ARE approved for other cancer types. For example, trastuzumab deruxtecan (an HER2-targeting ADC) is used in various cancers. If your carcinoid tumor has specific biomarkers (like HER2 expression), your oncologist might discuss whether an ADC could be considered off-label or through a clinical trial.

Questions to Ask Your Oncologist

1. Has my tumor been tested for HER2 expression or other biomarkers that might respond to antibody-drug conjugates?
2. Are there any clinical trials available for ADCs in carcinoid tumors?
3. What are the standard treatment options recommended for my specific type and stage of carcinoid tumor?
4. Would off-label use of an ADC be appropriate for my case?

According to the NCCN Guidelines, treatment decisions for carcinoid tumors should be individualized based on tumor location, grade, biomarkers, and disease burden.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.